The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Buckley, Michael T ^a   Yoon, Joanne ^a   Yee, Herman ^a   Chiriboga, Luis ^a   Liebes, Leonard ^a   Ara, Gulshan ^d   Qian, Xiaozhong ^d   Bajorin, Dean F ^c   Sun, Tung Tien ^a   Wu, Xue Ru ^a,b   Osman, Iman ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CURAGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; BELINOSTAT; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; HYDROXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER PAPILLOMA; CANCER INHIBITION; CELL COMMUNICATION; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HEMATURIA; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; BLADDER TUMOR; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; ORGAN SIZE; PATHOLOGY; TUMOR CELL LINE;

ACETYLCYSTEINE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN D1; CYTOPLASM; ENZYME INHIBITORS; FATTY ACIDS, UNSATURATED; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KARYOPHERINS; LEUPEPTINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; TRANSFECTION; UBIQUITIN; ANIMALS; CELL COMMUNICATION; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATURIA; HISTONE DEACETYLASES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; ORGAN SIZE; URINARY BLADDER NEOPLASMS;

EID: 36849084965     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-49     Document Type: Article

References (47)

1. Jemal A Tiwari RC Murray T Ghafoor A Samuels A Ward E Feuer EJ Thun MJ Cancer statistics, 2004 CA Cancer J Clin 2004, 54:8-29 14974761
2. Society AC. What are the key statistics for bladder cancer? http://seer.cancer.gov/statfacts/html/urinb.html Accessed January 2007
3. Earel JK VanOosten RL Griffith TS Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells Cancer Res 2006, 66:499-507 10.1158/0008-5472.CAN-05-3017 16397266
4. Kelly WK Richon VM O'Connor O Curley T MacGregor-Curtelli B Tong W Klang M Schwartz L Richardson S Rosa E Drobnjak M Cordon-Cordo C Chiao JH Rifkind R Marks PA Scher H Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 2003, 9:3578-88 14506144
5. Tumber A Collins LS Petersen KD Thougaard A Christiansen SJ Dejligbjerg M Jensen PB Sehested M Ritchie JW The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo Cancer Chemother Pharmacol 2007, 60:275-83 10.1007/s00280-006-0374-7 17124594
6. Plumb JA Finn PW Williams RJ Bandara MJ Romero MR Watkins CJ La Thangue NB Brown R Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 Mol Cancer Ther 2003, 2(8):721-728 12939461
7. Beck HC Nielsen EC Matthiesen R Jensen LH Sehested M Finn P Grauslund M Hansen AM Jensen ON Quantitative proteomic analysis of post-translational modifications of human histones Mol Cell Proteomics 2006, 5(7):1314-1325 10.1074/mcp.M600007-MCP200 16627869
8. Qian X LaRochelle WJ Ara G Wu F Petersen KD Thougaard A Sehested M Lichenstein HS Jeffers M Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies Mol Cancer Ther 2006, 5:2086-2095 10.1158/1535-7163.MCT-06-0111 16928830
9. Carducci MA Gilbert J Bowling MK Noe D Eisenberger MA Sinibaldi V Zabelina Y Chen TL Grochow LB Donehower RC Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120 hr infusion schedule Clin Cancer Res 2001, 7:3047-55 11595694
10. Sandor V Bakke S Robey RW Kang MH Blagosklonny MV Bender J Brooks R Piekarz RL Tucker E Figg WD Chan KK Goldspiel B Fojo AT Balcerzak SP Bates SE Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms Clin Cancer Res 2002, 8(3):718-728 11895901
11. Hansen M Gimsing P Rasmussen A Jensen PB Knudsen LM A Phase I Study of the Histone Deacetylase (HDAC) Inhibitor PXD101 in Patients with Advanced Hematological Tumors (abstract) J Clin Oncology. ASCO Annual Meeting Proceedings 2005, 16S:3137
12. Marks P Rifkind RA Richon VM Breslow R Miller T Kelly WK Histone deacetylases and cancer: Causes and therapies Nat Rev Cancer 2001, 1:194-202 10.1038/35106079 11902574
13. Wu XR Medina JJ Sun TT Selective interactions of UPIa and UPIb, two members of the transmembrane 4 superfamily, with distinct single transmembrane-domained proteins in differentiated urothelial cells J Biol Chem 1995, 270:29752-9 10.1074/jbc.270.50.29752 8530366
14. Zhang ZT Pak J Shapiro E Sun TT Wu XR Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma Cancer Res 1999, 59:3512-7 10416618
15. Zhang ZT Pak J Huang HY Shapiro E Sun TT Pellicer A Wu XR Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation Oncogene 2001, 20:1973-80 10.1038/sj.onc.1204315 11360181
16. Czerniak B Cohen GL Etkind P Deitch D Simmons H Herz F Koss LG Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas Hum Pathol 1992, 23(11):1199-1204 10.1016/0046-8177(92)90285-B 1427748
17. Fitzgerald JM Ramchurren N Rieger K Levesque P Silverman M Libertino JA Summerhayes IC Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors J Natl Cancer Inst 1995, 87(2):129-133 10.1093/jnci/87.2.129 7707384
18. Shapiro E Huang HY Wu XR Uroplakin and androgen receptor expression in the human fetal genital tract: Insights into the development of the vagina J Urol 2000, 164:1048-51 10.1016/S0022-5347(05)67247-3 10958738
19. Mo L Zheng X Huang HY Shapiro E Lepor H Cordon-Cardo C Sun TT Wu XR Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis J Clin Invest 2007, 117:314-325 1770948 17256055 10.1172/JCI30062
20. Wu XR Urothelial tumorigenesis: A tale of divergent pathways Nat Rev Cancer 2005, 5:713-25 10.1038/nrc1697 16110317
21. Nair S Xu C Shen G Hebbar V Gopalakrishnan A Hu R Jain MR Liew C Chan JY Kong AN Toxicogenomics of endoplasmic reticulum stress inducer tunicamycin in the small intestine and liver of Nrf2 knockout and C57BL/ 6J mice Toxicol Lett 2007, 168:21-39 10.1016/j.toxlet.2006.10.012 17127020
22. Hu R Xu C Shen G Jain MR Khor TO Gopalkrishnan A Lin W Reddy B Chan JY Kong AN Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray Life Sci 2006, 79:1944-55 10.1016/j.lfs.2006.06.019 16828809
23. Agus DB Cordon-Cardo C Fox W Drobnjak M Koff A Golde DW Scher HI Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence J Natl Cancer Inst 1999, 91:1869-76 10.1093/jnci/91.21.1869 10547394
24. Roth JM Akalu A Zelmanovich A Policarpio D Ng B MacDonald S Formenti S Liebes L Brooks PC Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo Am J Pathol 2005, 166:901-11 1602358 15743801
25. Hamilton AL Eder JP Pavlick AC Clark JW Liebes L Garcia-Carbonero R Chachoua A Ryan DP Soma V Farrell K Kinchla N Boyden J Yee H Zeleniuch-Jacquotte A Wright J Elliott P Adams J Muggia FM Proteasome inhibition with bortezomib (PS-341): A phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle J Clin Oncol 2005, 23:6107-16 10.1200/JCO.2005.01.136 16135477
26. Mungan NA Aben KK Schoenberg MP Visser O Coebergh JW Witjes JA Kiemeney LA Gender differences in stage-adjusted bladder cancer survival Urology 2000, 55:876-80 10.1016/S0090-4295(00)00523-9 10840099
27. Grossfeld GD Carroll PR Evaluation of asymptomatic microscopic haematuria Urol Clin North Am 1998, 25:661-76 10.1016/ S0094-0143(05)70055-0 10026773
28. Höti N Chowdhury W Hsieh JT Sachs MD Lupold SE Rodriguez R Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy Mol Ther 2006, 14:768-78 10.1016/ j.ymthe.2006.07.009 16990052
29. Kutko MC Glick RD Butler LM Coffey DC Rifkind RA Marks PA Richon VM LaQuaglia MP Histone Deacetylase Inhibitors Induce Growth Suppression and Cell Death in Human Rhabdomyosarcoma in vitro Clin Cancer Res 2003, 9:5749-55 14654560
30. Chen CL Sung J Cohen M Chowdhury WH Sachs MD Li Y Lakshmanan Y Yung BY Lupold SE Rodriguez R Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells J Pharmacol Exp Ther 2006, 319:533-42 10.1124/jpet.106.106658 16868035
31. Richon VM Sandhoff TW Rifkind RA Marks PA Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc Natl Acad Sci 2000, 97:10014-9 27656 10954755 10.1073/ pnas.180316197
32. Sawa H Murakami H Ohshima Y Sugino T Nakajyo T Kisanuki T Tamura Y Satone A Ide W Hashimoto I Kamada H Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad Brain Tumor Pathol 2001, 18:109-14 10.1007/BF02479423 11908866
33. Li GC Zhang X Pan TJ Chen Z Ye ZQ Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest Int J Urol 2006, 13:581-6 10.1111/j.1442-2042.2006.01344.x 16771729
34. Sanchez-Carbayo M Socci ND Charytonowicz E Lu M Prystowsky M Childs G Cordon-Cardo C Molecular profiling of bladder cancer using cDNA microarrays: Defining histogenesis and biological phenotypes Cancer Res 2002, 62:6973-80 12460915
35. Sowa Y Orita T Hiranabe-Minamikawa S Nakano K Mizuno T Nomura H Sakai T Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites Ann N Y Acad Sci 1999, 886:195-9 10.1111/ j.1749-6632.1999.tb09415.x 10667218
36. Gui CY Ngo L Xu WS Richon VM Marks PA Histone deacetylase (HDAC) inhibitor activation of p21WAF1involves changes in promoter-associated proteins, including HDAC1 Proc Natl Acad Sci USA 2004, 101:1241-6 337037 14734806 10.1073/pnas.0307708100
37. Chopin V Toillon RA Jouy N Le Bourhis X P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells Oncogene 2004, 23:21-9 10.1038/ sj.onc.1207020 14712207
38. Glaser KB Staver MJ Waring JF Stender J Ulrich RG Davidsen SK Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol Cancer Ther 2003, 2:151-63 12589032
39. Ghoshal K Datta J Majumder S Bai S Dong X Parthun M Jacob ST Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure Mol Cell Biol 2002, 22:8302-19 134057 12417732 10.1128/ MCB.22.23.8302-8319.2002
40. Pellegrini F Budman DR Review: Tubulin function, action of antitubulin drugs, and new drug development Cancer Invest 2005, 23:264-73 10.1081/ CNV-200055970 15948296
41. Chiba T Yokosuka O Fukai K Kojima H Tada M Arai M Imazeki F Saisho H Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells Oncology 2004, 66:481-491 10.1159/000079503 15452378
42. Qi J Zhu YQ Luo J Tao WH Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor World J Gastroenterol 2006, 12:7113-7 17131472
43. Melkonyan HS Chang WC Shapiro JP Mahadevappa M Fitzpatrick PA Kiefer MC Tomei LD Umansky SR SARPS: A family of secreted apoptosis-related proteins Proc Natl Acad Sci USA 1997, 94:13636-41 28358 9391078 10.1073/ pnas.94.25.13636
44. Qiao L Schaack J Shao J Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid Endocrinology 2006, 147:865-74 10.1210/en.2005-1030 16282359
45. Johnson AM Conover DL Huang J Messing EM Ning R O'Connell MJ Rossi MA Sun TT Wood RW Wu XR Reeder JE Early detection and measurement of urothelial tumors in mice Urology 2006, 67:1309-14 10.1016/ j.urology.2005.12.011 16765196
46. Gojo I Jiemjit A Trepel JB Sparreboom A Figg WD Rollins S Tidwell ML Greer J Chung EJ Lee MJ Gore SD Sausville EA Zwiebel J Karp JE Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 2007, 109:2781-90 17179232
47. Ramalingam SS Parise RA Ramananthan RK Lagattuta TF Musguire LA Stoller RG Potter DM Argiris AE Zwiebel JA Egorin MJ Belani CP Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies Clin Cancer Res 2007, 13:3605-10 10.1158/ 1078-0432.CCR-07-0162 17510206